What's Happening?
Bavarian Nordic has announced that the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) has exercised additional contract options valued at $97
million. These options are part of an existing agreement to supply a freeze-dried formulation of the JYNNEOS® smallpox vaccine. The contract will support the manufacturing and supply of these vaccines, including the production of additional bulk vaccine necessary to fulfill the contract. The freeze-dried doses are scheduled for delivery in 2027, completing the original order for 11.5 million doses. This development follows Bavarian Nordic's long-standing partnership with the U.S. government, which began nearly a decade ago to improve vaccine storage and transportation logistics. The company has been a key supplier of smallpox vaccines to the U.S. government, particularly during the monkeypox outbreak in 2022-2023.
Why It's Important?
This contract underscores the critical role of public-private partnerships in enhancing national health security. By securing a reliable supply of the JYNNEOS® vaccine, the U.S. government is bolstering its preparedness against potential biological threats, including smallpox and monkeypox. The freeze-dried formulation offers advantages in terms of storage and shelf life, which are crucial for long-term stockpiling and rapid deployment in emergencies. This development also highlights the strategic importance of maintaining a robust vaccine manufacturing capability within the U.S., ensuring that the country can respond swiftly to emerging health threats. For Bavarian Nordic, this contract represents a significant financial boost, contributing to an upgraded revenue forecast for 2026.
What's Next?
Bavarian Nordic is set to deliver the remaining doses of the freeze-dried JYNNEOS® vaccine by 2027. The company will continue to work closely with BARDA to ensure the successful execution of the contract. As the U.S. government continues to prioritize public health preparedness, further collaborations and contracts with vaccine manufacturers like Bavarian Nordic may be anticipated. Additionally, the successful implementation of this contract could lead to further advancements in vaccine technology and logistics, potentially setting a precedent for future public health initiatives.
